Abstract 30P
Background
Survival of breast cancer has improved and treatment related metabolic profile deterioration after neoadjuvant systemic treatment (NST) becomes important issues in cancer survivors. We sought to compare metabolic and immune changes in patients who underwent 6 months of neoadjuvant chemotherapy (NCT) and neoadjuvant endocrine therapy (NET).
Methods
Prospective, randomized, phase III trial (NEST) which compared 24 weeks of response of NCT with Adriamycin and cyclophosphamide followed by docetaxel and NET with goserelin and tamoxifen. Among them, 123 patients from NEST trial in Asan Medical Center were retrospectively reviewed to evaluate metabolic changes such as BMI, total cholesterol (TC), fasting glucose and blood pressure (BP) before/after NST and 3 years of follow up. NLR were checked before and after NST. WHO classification was used for BMI and BP was classified according to 2017 AHA guideline.
Results
The mean age of patients was 42 years old. Overweight group were significantly increased after NCT and recovered after 3 year follow up (8.2%, 12.0%, 6.9% respectively, p < 0.05). BMI changes were not observed in NET group (time p value= 0.110). The mean value of initial TC before NCT was 184.6mg/dL, 216.0 mg/dL after NCT (p < 0.05), 179.0 mg/dL after 3 years of treatment (p < 0.05, after vs 3 yrs.). In the NET group, the mean initial TC before NET was 185.0mg/dL, and decreased to 176.3 mg/dL after NET, and 179.4 mg/dL after 3 yrs follow up (p = 0.192). In the NCT group, the mean fasting glucose were significantly increased while NCT (95.2mg/dL to 108.8mg/dL, p < 0.05), and recovered after 3 year follow up (98.0 mg/dL, p < 0.05). In the NET group, the mean fasting glucose changes were not observed (97.0mg/dL, 98.4 mg/dL and 98.4 mg/dL respectively p > 0.05, all). There are no effect on HTN during NCT and NET (p > 0.05 respectively). NLR was increased from 2.0 to 4.4 after NCT (p < 0.05) and decreased from 2.1 to 1.6(p < 0.05) after NET.
Conclusions
Compared with no changes on NET, NCT causes worsening of metabolic profiles such as BMI, TC, and fasting glucose, which is recovered over 3 years. NLR was increased after NCT but decreased after NET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract